TY - JOUR
T1 - Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents
T2 - A single-center registry
AU - Rozemeijer, Rik
AU - Benedetto, Daniela
AU - Kraaijeveld, Adriaan O.
AU - Voskuil, Michiel
AU - Stein, Mèra
AU - Timmers, Leo
AU - Rittersma, Saskia Z.
AU - Agostoni, Pierfrancesco
AU - Doevendans, Pieter A.
AU - Stella, Pieter R.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/7
Y1 - 2018/7
N2 - Objective: To assess clinical outcomes of Amphilimus Sirolimus-Eluting Stents (A-SES) as compared to Zotarolimus-Eluting Stents (ZES) in complex real-world diabetic patients. Background: Patients with diabetes mellitus represent one of the most challenging scenarios with high rates of restenosis and stent thrombosis in the current era of drug-eluting stents. Hence, we assessed the safety of A-SES versus ZES in complex diabetic patients. Methods: In this observational study, we analyzed all consecutive patients with diabetes mellitus referred to our center from November 2012 to November 2014. The primary outcome was target-lesion failure at 1-year follow-up. Results: A total of 165 consecutive diabetic patients underwent percutaneous coronary intervention with A-SES or ZES for stable coronary artery disease in our tertiary center. Using the Kaplan Meier method the cumulative incidence of target-lesion failure was 6.7% (5.9% A-SES versus 7.5% ZES, p = 0.19) at 1-year follow-up. Event-free survival at 1. year follow-up was similar (89.4% A-SES vs. 83.3% ZES, p = 0.29). Interestingly, we did not find any cases of definite-, and only one case of probable stent thrombosis in this high risk cohort. Conclusion: In this real-world registry, A-SES and ZES seems to be associated with promising 1-year clinical safety outcomes following PCI in a contemporary cohort of high-risk diabetic patients. Our results should be considered hypothesis generating, as the clinical safety of A-SES has to be confirmed in a large trial.
AB - Objective: To assess clinical outcomes of Amphilimus Sirolimus-Eluting Stents (A-SES) as compared to Zotarolimus-Eluting Stents (ZES) in complex real-world diabetic patients. Background: Patients with diabetes mellitus represent one of the most challenging scenarios with high rates of restenosis and stent thrombosis in the current era of drug-eluting stents. Hence, we assessed the safety of A-SES versus ZES in complex diabetic patients. Methods: In this observational study, we analyzed all consecutive patients with diabetes mellitus referred to our center from November 2012 to November 2014. The primary outcome was target-lesion failure at 1-year follow-up. Results: A total of 165 consecutive diabetic patients underwent percutaneous coronary intervention with A-SES or ZES for stable coronary artery disease in our tertiary center. Using the Kaplan Meier method the cumulative incidence of target-lesion failure was 6.7% (5.9% A-SES versus 7.5% ZES, p = 0.19) at 1-year follow-up. Event-free survival at 1. year follow-up was similar (89.4% A-SES vs. 83.3% ZES, p = 0.29). Interestingly, we did not find any cases of definite-, and only one case of probable stent thrombosis in this high risk cohort. Conclusion: In this real-world registry, A-SES and ZES seems to be associated with promising 1-year clinical safety outcomes following PCI in a contemporary cohort of high-risk diabetic patients. Our results should be considered hypothesis generating, as the clinical safety of A-SES has to be confirmed in a large trial.
KW - Diabetes mellitus
KW - Drug-eluting stent
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85033606170&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2017.10.011
DO - 10.1016/j.carrev.2017.10.011
M3 - Article
C2 - 29137966
SN - 1878-0938
VL - 19
SP - 521
EP - 525
JO - Cardiovascular revascularization medicine : including molecular interventions
JF - Cardiovascular revascularization medicine : including molecular interventions
IS - 5
ER -